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Abstract
Purpose: Phyllodes tumours are rare breast tumours that comprise almost 1% of breast tumours. The outcome for 
these tumours is generally considered better than breast cancers. We review the cases of phyllodes tumour presenting 
to a specialised cancer centre over a 14-year period.
Materials and Methods: All case records with the diagnosis of phyllodes tumour between 1999 and 2012 were 
retrieved from the cancer registry. Patient demographics, tumour site, size, axillary lymph node status, whether 
primary or recurrent, metastatic status, histological type, type of surgery, any complication, margin positivity, post-
operative radiation therapy, local or distant recurrence, morality and follow-up duration were recorded. Data were 
analysed using SPSS.
Results: A total of 77 cases of phyllodes tumour were seen between 1999 and 2012. All patients were female with a 
mean age of 39.9 years. All patients presented with a breast lump with median duration of 8 months. Almost two-thirds 
(65%) of the patients presented with primary tumour compared to 10% recurrent tumours and the rest were referred 
after surgery outside. Median size on histopathology was 5 cm (IQR 3.5–8.5 cm). Over a median follow-up duration of 
31 months (IQR 9–48 months), 69 patients (89.6%) were alive, while 3 patients (3.9%) did not survive and 5 patients 
(6.4%) were lost to follow-up. Recurrence was seen in 10 (13%) patients with median time to recurrence of 12 months 
(IQR 7–24). Involved axillary lymph nodes and borderline or malignant histopathology were found to be significantly 
associated with recurrence (P = 0.04), while margin positivity, post-operative radiation therapy and histopathology 
were not significantly associated with recurrence.
Conclusion: Phyllodes tumour is an uncommon breast tumour that is predominantly treated with surgical excision. 
Although survival with these tumours is better compared to breast cancers, involvement of axillary nodes and 
borderline or malignant histopathology confer an increased risk of recurrence in these patients.
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Introduction
Phyllodes tumour or cystosarcoma phyllodes is a rare 
breast lesion comprising <1% of all breast tumours.[1,2] 
The usual presentation is a rapidly enlarging mass in a 
young female, which is often misdiagnosed and treated 
as fibroadenoma. Quite often, the diagnosis is revealed 
on histopathology of a presumed fibroadenoma after 
excision. Pathologically, it varies from benign to 
borderline or malignant form depending on its size and 
histological features including mitotic rates.[3] Opinion 
varies in literature regarding the treatment options, 
adequate resection margins and role of radiation therapy 
in prevention of recurrence in this disease.[4-6] There is still 
controversy about the biological behaviour of borderline 
and malignant tumours in terms of survival and recurrence.
The most universally acceptable classification system 
based on pathological features for phyllodes tumours is 
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according to the criteria proposed by Azzopardi[3] and 
Salvadori et al.[5] This classifies these tumours into benign, 
borderline or malignant based on tumour margins, stromal 
hypercellularity, stromal overgrowth, tumour necrosis, 
cellular atypia and mitotic rates per 10 high-power fields.
The incidence of breast cancer in Pakistan is one of the 
highest in reported literature.[7] With limited resources 
and a paucity of specialised centres for the treatment of 
breast cancer, phyllodes tumour is infrequently seen. The 
purpose of this study was to review clinical presentation, 
workup, management plan, histopathological features and 
subsequent follow-up of patients with phyllodes tumour 
presenting to a specialised breast cancer unit.
Materials and Methods
A retrospective chart review was performed including 
all patients with phyllodes tumour presenting to Shaukat 
Khanum Memorial Cancer Hospital and Research Centre, 
Lahore. Some of these patients presented with established 
diagnosis of phyllodes after initial surgery or biopsy of the 
breast mass elsewhere, while the rest were primarily seen 
for breast masses and were diagnosed to have phyllodes 
tumour on the workup of these lesions.
All case records with the diagnosis of phyllodes tumour 
between 1999 and 2013 were retrieved from the cancer 
registry. A total of 100 patients were identified who had 
diagnosis of phyllodes. Of these, 77 cases that underwent 
surgical treatment at our institution were included in the 
study. Patient demographics, tumour site, size, axillary lymph 
node status, primary or recurrent disease, metastatic status, 
histological type, extent of surgical excision, post-operative 
complications, margin positivity, post-operative radiation 
therapy, local or distant recurrence, morality and follow-up 
duration were recorded. These variables were compared to 
evaluate any significant difference between patients with 
benign, borderline and malignant tumours, and also to find 
any association with the development of recurrent disease.
Kaplan–Meier analysis was conducted to determine 
if there was any difference in survival between the 
different pathological groups. Pearson Chi-square test 
was used to see any relationship of recurrence with size 
and histopathology. All statistical analyses were carried 
out using SPSS (Version19 SPSS Inc., Chicago, USA).
Results
A total of 77 cases of phyllodes tumour were reviewed 
in this study who presented for treatment between 1999 
and 2013. All patients were female with a mean age of 
39.9 years (range 16–65 years). Of these patients, 22.1% 
were <30 years of age, while 15.6% of these were over 
50 years of age. The patient population presented from 
all areas of Pakistan, but majority (84.4%) belonged to 
Punjab. All patients presented with a breast lump with 
median duration of 8 months. A history of breast lump 
for >2 years was present in 19.7% of the patients. The 
distribution of lesions was equal in both breasts (38 right 
sided vs. 39 left sided). 10 patients (13%) were unmarried 
at the time of diagnosis.
Histopathology of patients revealed benign tumours in 
31 cases (40.3%) and borderline in 22 cases (28.6%) while 
remaining 24 cases (31.2%) were malignant [Table 1].
Forty-four (57.1%) patients were treated primarily at out 
institution as they presented with a palpable breast mass 
and were worked up for this complaint. Of the remaining 
patients, 28 (36.4%) had undergone initial surgery outside, 
whereas 5 (6.5%) presented with recurrent disease. A total 
of 42 cases underwent single surgery while others had two 
or more procedures done for either recurrence or positive 
margins. Amongst these, 26 patients underwent wide local 
excision (WLE), four had simple mastectomy and four 
had sentinel node biopsy with simple mastectomy. Six 
patients underwent modified radical mastectomy (MRM) 
as the first procedure, one patient underwent WLE with 
axillary sampling performed and one had WLE with 
axillary dissection performed. The reason for axillary 
nodal sampling or dissection was palpable lymph nodes 
and large size of the tumours.
Seven patients were initially operated elsewhere and 
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had initially undergone lumpectomy. Two had benign 
lesion and five had borderline lesions. They underwent 
WLE (two patients; one benign and one borderline) or 
mastectomy (one benign, large lesion and three borderline 
lesions). 12 patients were also referred from other hospitals 
after excision with involved or close margins of malignant 
phyllodes. Of these six patients underwent reexcision, four 
had mastectomy and two underwent MRM as they had 
palpable lymph nodes on presentation.
The mean age for patients with borderline phyllodes was 
38 years (range 20–60). Mean duration of symptom at 
presentation was 17.3 months. Three patients had palpable 
axillary nodes at presentation, but final histopathology 
did not reveal any involved lymph nodes. WLE was 
performed in 18 patients as the first procedure. One 
patient underwent simple mastectomy, one underwent 
mastectomy with sentinel lymph node biopsy and two 
patients underwent MRM. Of all patients with borderline 
phyllodes, 12 patients primarily presented to our hospital 
(nine underwent WLE; one each had mastectomy, SLN 
with mastectomy and MRM). Two patients had reexcision 
for positive margins. There were four patients who had 
recurrence of borderline phyllodes in the same breast. 
Two patients had clear margins after the first surgery 
and two required reexcision for involved margins. Only 
one of them had post-operative radiation therapy and 
subsequently developed recurrence. The other three 
patients did not receive radiation therapy. One patient 
had reported mortality in borderline group due to non-
cancer-related cause. She had clear margins at resection 
and had no recurrence.
Amongst patients with malignant phyllodes (24), WLE 
was initial procedure in 15 patients. Five had clear margins 
and 10 had to undergo repeat surgery due to involved 
or close margins. Disease recurrence was seen in five 
patients. Three had lung metastasis, of these two patients 
had documented mortality and one was lost to follow-
up. There were 18 patients in this group who underwent 
post-operative radiation therapy. The reasons for offering 
adjuvant radiation therapy were individualised in each 
case based on discussion in the multidisciplinary team 
meeting, but most commonly was size and close margins. 
One patient amongst these developed diseases recurrence 
requiring reexcision, while another patient developed 
lung metastasis.
Median size on histopathology was 5 cm (IQR 3.5–
8.5 cm). Of 67 cases, where histopathologic specimen 
size was mentioned, 31 patients had size between 5 and 
10 cm and 10 patients had >10 cm neoplasm.
The median follow-up duration of all patients was 
31 months (IQR 9–48 months). Survival was calculated 
with Kaplan–Meir’s chart. Benign phyllodes had 100% 
while malignant phyllodes had 91.5% survival during the 
follow-up time [Figure 1].
Recurrence was seen in 10 (13%) patients with median time 
to recurrence 12 months (IQR 7–24). Involved axillary 
lymph nodes and borderline or malignant histopathology 
were found to be significantly associated with recurrence 
(P = 0.04). Margin positivity and post-operative radiation 
therapy were not significantly associated with recurrence.
Discussion
Phyllodes are a rare tumour of breast. It is reported to 
account for <1% of all female breast tumours.[8] Even 
in a country like Pakistan where breast cancer incidence 
is reported to be on the rise, there are few case series 
reported, suggesting the infrequent occurrence of these 
tumours. Phyllodes have variable histopathologic 
characteristics. The histopathological characteristics 
have mainly been the basis for different histological 
Figure 1: Survival curves for patients with benign, borderline 
and malignant phyllodes tumour
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classifications, most notably by Treves et al.,[9] Pietruszka 
and Barnes[10] and separately by Azzopardi[3] and Salvadori 
et al.[5] The World Health Organisation classifies these 
tumours as low, intermediate and high grade based on 
histology.[11] Most important histopathological features 
considered in these classifications are size, number of 
mitosis per high-power field, invading nature of margins 
and nuclear features of cells.
Clinical history of patients with phyllodes tumour is also 
variable; most commonly as slow-growing tumours, 
with occasional rapid growth resulting in being noticed 
by the patient. Patients normally do not have any skin 
involvement or lymph node enlargement. Quite often, 
these tumours are diagnosed on histopathology of breast 
lumps removed with clinical diagnosis of fibroadenoma. 
Unlike fibroadenoma, a significant percentage (10–40%) 
of these lesions has malignant potential and tendency for 
recurrence.[12]
We observed that the mean age of our patients was 
39.9 years and only 22% of our patients were <30 years. 
Similar age group was reported by other reviews.[13] A study 
by Tan et al.[14] reported the mean age of 41.4 years, with 
42.3% of cases younger than 40 years of age. A comparison 
between Asian and Western population by Chua et al.[15] 
showed Asian phyllodes patient to be a young female, aged 
25–30 years, whereas her Western counterpart is in her 
40s. SEER data showed that their patients had a median 
age of 50 (range 12–96).[16] In comparison, patients at our 
institution presented mostly with slow-growing tumours 
with an average duration of the symptoms of 8 months. 
Almost 20% of patients had a lump for >2 years before 
any treatment was started. This delay in presentation 
most likely represents a lack of awareness amongst our 
population regarding breast complaints.
We observed that histopathology of patients revealed 
benign in 40% of cases, while remaining were either 
borderline 28.6% or malignant 31%. Tan et al.[14] reported 
benign cases up to 74.6%, borderline 16.1% and malignant 
9.3% in their observed group. Another study from Pakistan 
by Khurshid et al.[17] reported benign 19.1%, borderline 
21.9% and malignant 19.7% in their study group.
Our patients with benign phyllodes had 100% while 
malignant phyllodes have 91.5% survival during the 
follow-up period. In comparison, a recent study from 
Taiwan reported a 5-year disease-free survival was 59% 
and the 5-year overall survival to be 81%.[18]
In our study, recurrence was seen in 10 (13%) patients 
with median time to recurrence 12 months. A study 
from Japan[19] with a median duration of follow-up 
of 101 months (range 1–273 months) showed local 
recurrence in six patients (n = 45); 5-, 10- and 15-year 
cumulative local recurrence-free rates were 88, 88 and 
84%, respectively, and the cumulative disease-free 
rates were 85, 85 and 81%, respectively. Another study 
from the United States showed that for patients with 
non-malignant (benign or indeterminate) and malignant 
phyllodes, the overall survival was 91% and 82%, 
respectively, at 5 years, and 79% and 42%, respectively, 
at 10 years.[8]
We observed that involved axillary lymph nodes and 
borderline or malignant histopathology were significantly 
associated with recurrence (P = 0.04), while margin 
positivity and post-operative radiation therapy were not 
associated with recurrence in our series. In comparison, 
a study by Taira et al. from Japan[19] showed the surgical 
margin (P = 0.0034), stromal overgrowth (P = 0.0003) 
and histological classification (P =0.026) as significant 
predictive factors for local recurrence in univariate 
analysis. However, in multivariate analysis, the surgical 
margin was the only independent predictive factor for 
local recurrence (P = 0.026). Various other studies have 
shown local recurrence rates up to 15–20% and showed 
its association with positive excision margins, rather than 
with tumour grade or size.[20,21]
There is no defined treatment strategy for phyllodes 
tumours and different centres have reported variable 
outcome with surgery alone, chemotherapy with surgery 
or radiation with surgery.[22]
Some experts consider radiation for borderline 
tumours excised initially with involved close margins, 
while other offer radiation therapy to only malignant 
phyllodes or recurrent benign and borderline tumours. 
Patients with phyllodes tumour have a favourable 
prognosis compared to other breast cancers. Mortality is 
usually associated with metastatic disease or recurrent 
malignant disease.
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Conclusion
Phyllodes tumour is an uncommon breast tumour that is 
predominantly treated with surgical excision. Although 
survival with these tumours is better compared to breast 
cancers, involvement of axillary nodes and borderline 
or malignant histopathology confer an increased risk of 
recurrence in these patients.
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